DE69232967D1 - Vaccines against papillomavirus - Google Patents

Vaccines against papillomavirus

Info

Publication number
DE69232967D1
DE69232967D1 DE69232967A DE69232967A DE69232967D1 DE 69232967 D1 DE69232967 D1 DE 69232967D1 DE 69232967 A DE69232967 A DE 69232967A DE 69232967 A DE69232967 A DE 69232967A DE 69232967 D1 DE69232967 D1 DE 69232967D1
Authority
DE
Germany
Prior art keywords
vaccines against
against papillomavirus
papillomavirus
vaccines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69232967A
Other languages
German (de)
Other versions
DE69232967T2 (en
DE122007000016I1 (en
Inventor
Ian Frazer
Jian Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
QUEENSLAND SANTA LUCIA, University of
CLS Ltd
Original Assignee
UNIV QUEENSLAND SANTA LUCIA
CLS Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to AUPK732291 priority Critical
Application filed by UNIV QUEENSLAND SANTA LUCIA, CLS Ltd filed Critical UNIV QUEENSLAND SANTA LUCIA
Priority to PCT/AU1992/000364 priority patent/WO1993002184A1/en
Application granted granted Critical
Publication of DE69232967D1 publication Critical patent/DE69232967D1/en
Anticipated expiration legal-status Critical
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3775561&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69232967(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application status is Expired - Lifetime legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701Specific hybridization probes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses
    • C12N2710/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses dsDNA Viruses
    • C12N2710/20011Papillomaviridae
    • C12N2710/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses
    • C12N2710/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses dsDNA Viruses
    • C12N2710/20011Papillomaviridae
    • C12N2710/20023Virus like particles [VLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses
    • C12N2710/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses dsDNA Viruses
    • C12N2710/20011Papillomaviridae
    • C12N2710/20034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses
    • C12N2710/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses dsDNA Viruses
    • C12N2710/20011Papillomaviridae
    • C12N2710/20041Use of virus, viral particle or viral elements as a vector
    • C12N2710/20043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/70Nanostructure
    • Y10S977/788Of specified organic or carbon-based composition
    • Y10S977/802Virus-based particle
DE69232967A 1991-07-19 1992-07-20 Vaccines against papillomavirus Expired - Lifetime DE69232967D1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AUPK732291 1991-07-19
PCT/AU1992/000364 WO1993002184A1 (en) 1991-07-19 1992-07-20 Papilloma virus vaccine

Publications (1)

Publication Number Publication Date
DE69232967D1 true DE69232967D1 (en) 2003-04-24

Family

ID=3775561

Family Applications (14)

Application Number Title Priority Date Filing Date
DE1992633639 Pending DE122007000018I1 (en) 1991-07-19 1992-07-20 Polynucleotide segment of the HPV16 genome
DE122007000085C Pending DE122007000085I1 (en) 1991-07-19 1992-07-20 Polynucleotide segment of the HPV16 genome
DE200712000023 Pending DE122007000023I1 (en) 1991-07-19 1992-07-20 Impfsstoff against human papilloma virus (type 18)
DE122007000084C Pending DE122007000084I1 (en) 1991-07-19 1992-07-20 Vaccine against human papilloma virus (type 18)
DE1992632967 Pending DE122007000016I1 (en) 1991-07-19 1992-07-20 Vaccines against papillomavirus
DE200712000019 Pending DE122007000019I1 (en) 1991-07-19 1992-07-20 Vaccines against papillomavirus
DE122007000086C Pending DE122007000086I1 (en) 1991-07-19 1992-07-20 Vaccine against human papilloma virus (type 18)
DE69233639T Expired - Lifetime DE69233639T2 (en) 1991-07-19 1992-07-20 Polynucleotide segment of the HPV16 genome
DE200712000017 Pending DE122007000017I1 (en) 1991-07-19 1992-07-20 Vaccines against papillomavirus
DE69232967A Expired - Lifetime DE69232967D1 (en) 1991-07-19 1992-07-20 Vaccines against papillomavirus
DE69233687A Expired - Lifetime DE69233687D1 (en) 1991-07-19 1992-07-20 Vaccine against human papilloma virus (type 18)
DE69232967T Expired - Lifetime DE69232967T2 (en) 1991-07-19 1992-07-20 Vaccines against papillomavirus
DE69233687T Expired - Lifetime DE69233687T2 (en) 1991-07-19 1992-07-20 Vaccine against human papilloma virus (type 18)
DE69233639A Expired - Lifetime DE69233639D1 (en) 1991-07-19 1992-07-20 Polynucleotide segment of the HPV16 genome

Family Applications Before (9)

Application Number Title Priority Date Filing Date
DE1992633639 Pending DE122007000018I1 (en) 1991-07-19 1992-07-20 Polynucleotide segment of the HPV16 genome
DE122007000085C Pending DE122007000085I1 (en) 1991-07-19 1992-07-20 Polynucleotide segment of the HPV16 genome
DE200712000023 Pending DE122007000023I1 (en) 1991-07-19 1992-07-20 Impfsstoff against human papilloma virus (type 18)
DE122007000084C Pending DE122007000084I1 (en) 1991-07-19 1992-07-20 Vaccine against human papilloma virus (type 18)
DE1992632967 Pending DE122007000016I1 (en) 1991-07-19 1992-07-20 Vaccines against papillomavirus
DE200712000019 Pending DE122007000019I1 (en) 1991-07-19 1992-07-20 Vaccines against papillomavirus
DE122007000086C Pending DE122007000086I1 (en) 1991-07-19 1992-07-20 Vaccine against human papilloma virus (type 18)
DE69233639T Expired - Lifetime DE69233639T2 (en) 1991-07-19 1992-07-20 Polynucleotide segment of the HPV16 genome
DE200712000017 Pending DE122007000017I1 (en) 1991-07-19 1992-07-20 Vaccines against papillomavirus

Family Applications After (4)

Application Number Title Priority Date Filing Date
DE69233687A Expired - Lifetime DE69233687D1 (en) 1991-07-19 1992-07-20 Vaccine against human papilloma virus (type 18)
DE69232967T Expired - Lifetime DE69232967T2 (en) 1991-07-19 1992-07-20 Vaccines against papillomavirus
DE69233687T Expired - Lifetime DE69233687T2 (en) 1991-07-19 1992-07-20 Vaccine against human papilloma virus (type 18)
DE69233639A Expired - Lifetime DE69233639D1 (en) 1991-07-19 1992-07-20 Polynucleotide segment of the HPV16 genome

Country Status (17)

Country Link
US (5) US7476389B1 (en)
EP (5) EP0595935B1 (en)
JP (3) JP3828570B2 (en)
KR (1) KR100240480B1 (en)
AT (3) AT356142T (en)
AU (1) AU651727B2 (en)
CA (1) CA2113712C (en)
CY (1) CY2598B2 (en)
DE (14) DE122007000018I1 (en)
DK (3) DK1359156T3 (en)
ES (3) ES2279020T3 (en)
GE (1) GEP20084431B (en)
HK (1) HK1059271A1 (en)
LU (8) LU91315I2 (en)
NL (8) NL300260I1 (en)
SG (1) SG48769A1 (en)
WO (1) WO1993002184A1 (en)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100240480B1 (en) 1991-07-19 2000-03-02 터베이 피터 Papilloma virus vaccine
DE69334192T2 (en) * 1992-06-25 2008-12-04 Georgetown University papillomavirus vaccine-
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
AU717647B2 (en) * 1994-10-06 2000-03-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Chimeric papillomavirus-like particles
US20020164350A1 (en) 1992-09-03 2002-11-07 Lowy Douglas R. Chimeric papillomavirus-like particles
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
DE69434383T2 (en) * 1993-03-09 2005-11-24 The University Of Rochester Production of human papillomavirus coat protein and virus-like particles
US8062642B1 (en) 1993-03-09 2011-11-22 University Of Rochester Production of papillomavirus capsid protein and virus-like particles
AU719837B2 (en) * 1993-03-31 2000-05-18 Cancer Research Campaign Technology Limited Pharmaceuticals based on papillomaviruses
GB9306731D0 (en) * 1993-03-31 1993-05-26 Cancer Res Campaign Tech Vaccines
GB2279651A (en) * 1993-07-01 1995-01-11 British Tech Group Synthetic peptides of human papillomavirus
GB9313556D0 (en) * 1993-07-01 1993-08-18 British Tech Group Synthetic peptides of human papillomavirus
AUPM358894A0 (en) * 1994-01-31 1994-02-24 Csl Limited Modified papilloma virus l2 protein and vlps formed therefrom
DE4415743C2 (en) 1994-05-04 1996-10-10 Deutsches Krebsforsch Papillomaviruses, means for their detection as well as for the therapy of diseases caused by them
US5888516A (en) * 1994-05-16 1999-03-30 Merck & Co. Inc. Recombinant papillomavirus vaccines
PL183781B1 (en) * 1994-05-16 2002-07-31 Merck & Co. Inc. Vaccines against papilloma virus
AUPM566794A0 (en) * 1994-05-17 1994-06-09 University Of Queensland, The Process and product
IL113817A (en) * 1994-06-30 2001-03-19 Merck & Co Inc Polynucleotide vaccne for papillomavirus
AU717932B2 (en) * 1994-10-06 2000-04-06 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Chimeric papillomavirus-like particles
AU2003235191B2 (en) * 1994-10-07 2006-09-21 Loyola University Of Chicago Papilloma virus-like particles, fusion proteins as well as processes for their production
DE122007000093I1 (en) * 1994-10-07 2008-03-27 Univ Loyola Chicago Papilloma virus particle, fusion proteins and methods for their preparation
DE4447664C2 (en) * 1994-10-07 1999-04-15 Lutz Prof Dr Gissmann Recombinant papilloma virus-like particles contg. L1 or L2 proteins
AR004464A1 (en) * 1994-11-14 1998-12-16 Merck Sharp & Dohme A method of producing a capsid protein of papillomavirus
US6908615B1 (en) 1996-03-18 2005-06-21 Merck & Co., Inc. DNA encoding human papilloma virus type 18
US5820870A (en) * 1995-03-22 1998-10-13 Merck & Co., Inc. Recombinant human papillomavirus type 18 vaccine
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
US5840306A (en) * 1995-03-22 1998-11-24 Merck & Co., Inc. DNA encoding human papillomavirus type 18
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
US5821087A (en) * 1995-03-30 1998-10-13 Merck & Co., Inc. Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
IL117591D0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
SE9501512D0 (en) * 1995-04-24 1995-04-24 Euro Diagnostica Ab Synthetic peptide-defined eptopes Useful for vaccination against papillomaviruses
DE19526752C2 (en) * 1995-07-21 1997-08-07 Lutz Prof Dr Gissmann High-efficiency formation of papilloma virus-like particles
ES2213185T3 (en) * 1995-11-15 2004-08-16 MERCK & CO., INC. HPV11 virus-like particles synthetics.
FR2749323B1 (en) * 1996-06-04 1998-07-10 Pasteur Merieux Serums Vacc virus-like particles useful as a delivery vector nucleic acid
FR2751879B1 (en) * 1996-07-30 1998-10-30 Transgene Sa A pharmaceutical composition against tumors and infections papillomavirus
US7118754B1 (en) 1996-07-30 2006-10-10 Transgene S.A. Pharmaceutical composition for treating papillomavirus tumors and infection
WO1998014564A1 (en) * 1996-10-04 1998-04-09 Merck & Co., Inc. Synthetic hpv16 virus-like particles
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
WO1998025646A1 (en) * 1996-12-09 1998-06-18 Merck & Co., Inc. Synthetic hpv16 virus-like particles
EP0957936B1 (en) * 1996-12-20 2006-10-04 MERCK & CO., INC. Formulations of recombinant papillomavirus vaccines
EP0980257A1 (en) * 1997-05-01 2000-02-23 Chiron Corporation Use of virus-like particles as adjuvants
JP2002510976A (en) * 1997-07-03 2002-04-09 メディムーン・インコーポレイテッド Compositions containing capsomeres of homogeneous human papillomavirus, methods for their preparation, and their diagnostic, prophylactic, therapeutic use
FR2766091A1 (en) 1997-07-18 1999-01-22 Transgene Sa An antitumor composition was immunogenic polypeptide basic cellular localization modified
US6962777B1 (en) * 1997-09-05 2005-11-08 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps), homogeneous vlp and capsomere compositions produced by said methods; use thereof as vehicle for improved purification, and delivery of active agents
US6228368B1 (en) 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
CA2229955C (en) 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
AUPP765398A0 (en) 1998-12-11 1999-01-14 University Of Queensland, The Treatment of papillomavirus infections
DE19925235A1 (en) 1999-06-01 2000-12-07 Medigene Ag Cytotoxic T cell epitopes of the papilloma virus L1 protein and its use in diagnosis and therapy
DE19925234A1 (en) * 1999-06-01 2000-12-14 Medigene Ag Capsomers, stable capsomeres, capsids, VLPs, or CVLPs or so loaded cells and their use in diagnosis and therapy
DE19925199A1 (en) 1999-06-01 2000-12-07 Medigene Ag Cytotoxic T cell epitopes of the papilloma virus L1 protein and its use in diagnosis and therapy
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
AUPR446801A0 (en) 2001-04-18 2001-05-17 University Of Queensland, The Novel compositions and uses therefor
KR100785397B1 (en) 2001-06-28 2007-12-13 아피메즈 주식회사 Recombinant adenoviral vector expressing HPV-like particles and live vaccine for cervical cancer prepared therefrom
DE10137102A1 (en) 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalent vaccine against diseases caused by papilloma viruses, processes for their preparation and their use
US7247433B2 (en) 2001-08-13 2007-07-24 University Of Rochester Transcutaneous immunization against papillomavirus with papillomavirus virus-like particles
EP1427443A4 (en) * 2001-08-23 2006-03-08 Merck & Co Inc Vaccine using papilloma virus e proteins delivered by viral vector
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
CA2531773A1 (en) 2003-07-21 2005-02-17 Transgene S.A. Novel multifunctional cytokines
JP4498357B2 (en) * 2003-09-25 2010-07-07 サード・ウェーブ・テクノロジーズ・インク Detection method of Hpv
CN101010099B (en) * 2004-09-10 2011-11-09 国立大学法人金沢大学 Edible vaccine
US8021992B2 (en) * 2005-09-01 2011-09-20 Taiwan Semiconductor Manufacturing Co., Ltd. High aspect ratio gap fill application using high density plasma chemical vapor deposition
TWI457133B (en) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa Novel composition
US8080643B2 (en) * 2006-09-05 2011-12-20 Third Wave Technologies, Inc. HPV primers
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
EP2486938B1 (en) 2006-09-26 2018-05-09 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US8052968B2 (en) 2006-10-16 2011-11-08 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods
SG194360A1 (en) 2007-03-02 2013-11-29 Glaxosmithkline Biolog Sa Novel method and compositions
MX344751B (en) * 2007-11-23 2017-01-05 Shanghai Zerun Biotechnology Co Ltd Genes encoding major capsid protein l1 of human papilloma virus's.
CN101952436B (en) 2008-01-09 2013-03-13 建国大学校产学协力团 Baculovirus-based vaccines
CA2722847A1 (en) 2008-05-26 2010-07-15 Cadila Healthcare Limited Combined measles-human papilloma vaccine
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
GB0820822D0 (en) 2008-11-13 2008-12-24 Inst Catala D Oncologia Novel product and processes
US20120115207A1 (en) * 2009-04-03 2012-05-10 Deutsches Krebsforschungszentrum Enhanced production of papillomavirus-like particles with a modified baculovirus expression system
EP3124491A1 (en) 2009-06-05 2017-02-01 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants and vaccine compositions containing them
AU2009348078B2 (en) 2009-06-19 2013-03-14 Eyegene Inc. Vaccine for cervical cancer
WO2011026111A1 (en) 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oral delivery of a vaccine to the large intestine to induce mucosal immunity
EP3242135A1 (en) 2010-04-08 2017-11-08 University of Pittsburgh - Of the Commonwealth System of Higher Education B-cell antigen presenting cell assay
EP2576840B1 (en) 2010-05-25 2018-10-17 QIAGEN Gaithersburg, Inc. Fast results hybrid capture assay and associated strategically-truncated probes
KR101349291B1 (en) 2010-08-10 2014-01-10 한국생명공학연구원 A method for producing cervical cancer vaccine using Bacillus subtilis
EA027236B1 (en) 2011-04-08 2017-07-31 Иммьюн Дизайн Корп. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
WO2013139744A1 (en) 2012-03-18 2013-09-26 Glaxosmithkline Biologicals S.A. Method of vaccination against human papillomavirus
LT2850431T (en) 2012-05-16 2018-06-25 Immune Design Corp. Vaccines for hsv-2
WO2014066443A1 (en) 2012-10-23 2014-05-01 Emory University Gm-csf and il-4 conjugates, compositions, and methods related thereto
CN105209047A (en) 2013-04-18 2015-12-30 免疫设计股份有限公司 GLA monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US20180078634A1 (en) * 2015-03-18 2018-03-22 The University Of Massachusetts Virus-like particle compositions and vaccines against epstein-barr virus infection and disease
KR101908438B1 (en) * 2016-02-05 2018-10-16 (주)피앤피바이오팜 A MANUFACTURING METHOD FOR SOLUBLE AND ACTIVE RECOMBINANT PROTEIN USING Aminoacyl tRNA synthetase N-terminal domain AS FUSION PARTNER AND A PRODUCT THEREOF
US20170241998A1 (en) 2016-02-22 2017-08-24 Boehringer Ingelheim Vetmedica Gmbh Method for the immobilization of biomolecules
WO2017200957A1 (en) 2016-05-16 2017-11-23 Infectious Disease Research Institute Pegylated liposomes and methods of use
AU2017268144A1 (en) 2016-05-16 2018-11-29 Infectious Disease Research Institute Formulation containing TLR agonist and methods of use
WO2017210364A1 (en) 2016-06-01 2017-12-07 Infectious Disease Research Institute Nanoalum particles containing a sizing agent
RU2681174C1 (en) * 2018-07-12 2019-03-04 Закрытое акционерное общество научно-производственная компания "Комбиотех" Method of obtaining a recombinant vaccine for prevention of humanpapilloma virus infection, recombinant vaccine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2524487B1 (en) 1982-04-05 1985-11-22 Pasteur Institut DNA fragments encoding polypeptides containing at least one antigenic determinant of papillomavirus, particularly of the type HPV 1a and corresponding polypeptides
US5071757A (en) 1986-10-06 1991-12-10 Kreider John W Methods for propagating fastidious human viruses and for producing purified suspensions thereof
US5045447A (en) 1989-03-15 1991-09-03 Minson Anthony C Method of producing antibodies to HPV
NL8902301A (en) * 1989-09-14 1991-04-02 Rijksuniversiteit Human parvovirus B19 proteins, their production and their use in diagnostic assays and vaccines.
WO1992016638A1 (en) * 1991-03-14 1992-10-01 5 Prime --> 3 Prime, Inc. Transduction vehicles for transferring dna to a mammalian cell
KR100240480B1 (en) * 1991-07-19 2000-03-02 터베이 피터 Papilloma virus vaccine
DE69334192T2 (en) 1992-06-25 2008-12-04 Georgetown University papillomavirus vaccine-
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
DE69434383T2 (en) 1993-03-09 2005-11-24 The University Of Rochester Production of human papillomavirus coat protein and virus-like particles

Also Published As

Publication number Publication date
EP1298211A2 (en) 2003-04-02
SG48769A1 (en) 1998-05-18
US20040214331A1 (en) 2004-10-28
DE122007000084I1 (en) 2008-03-27
DK0595935T3 (en) 2003-07-21
ES2279020T3 (en) 2007-08-16
DE122007000018I1 (en) 2007-05-24
LU91318I2 (en) 2007-04-27
WO1993002184A1 (en) 1993-02-04
EP1471147A2 (en) 2004-10-27
DE69233639T2 (en) 2007-05-31
CA2113712C (en) 2007-06-12
LU91387I2 (en) 2008-02-14
DK1359156T3 (en) 2007-04-10
EP1359156B1 (en) 2007-03-07
NL300261I1 (en) 2007-05-01
LU91318A9 (en)
LU91316A9 (en)
JP2006115849A (en) 2006-05-11
KR100240480B1 (en) 2000-03-02
NL300263I1 (en) 2007-05-01
US7939082B2 (en) 2011-05-10
EP0595935A4 (en) 1995-03-29
DE69233687D1 (en) 2007-04-19
LU91321A9 (en)
LU91387A9 (en)
DK1298211T3 (en) 2006-11-13
HK1059271A1 (en) 2007-06-29
AT332973T (en) 2006-08-15
LU91315A9 (en)
CA2113712A1 (en) 1993-02-04
JP3828570B2 (en) 2006-10-04
DE69232967T2 (en) 2003-12-18
DE122007000086I1 (en) 2008-04-17
US20070154902A1 (en) 2007-07-05
CY2598B2 (en) 2010-03-03
EP0595935B1 (en) 2003-03-19
ES2267890T3 (en) 2007-03-16
LU91317I2 (en) 2007-04-27
GEP20084431B (en) 2008-07-25
DE122007000085I1 (en) 2008-03-27
AU651727B2 (en) 1994-07-28
LU91386A9 (en)
JPH07505042A (en) 1995-06-08
EP1471147A3 (en) 2007-03-21
AU2366692A (en) 1993-02-23
EP0595935A1 (en) 1994-05-11
AT234925T (en) 2003-04-15
EP1207203A3 (en) 2004-04-28
LU91386I2 (en) 2008-02-14
DE122007000023I1 (en) 2007-08-09
US6613557B1 (en) 2003-09-02
DE122007000017I1 (en) 2007-07-26
US20090252761A1 (en) 2009-10-08
EP1359156A2 (en) 2003-11-05
US7169585B2 (en) 2007-01-30
LU91315I2 (en) 2007-04-27
EP1359156A3 (en) 2004-03-24
LU91316I2 (en) 2007-04-27
NL300314I1 (en) 2008-02-01
DE122007000019I1 (en) 2007-07-26
JP4255944B2 (en) 2009-04-22
NL300314I2 (en) 2010-03-01
LU91317A9 (en)
ES2194839T3 (en) 2003-12-01
AT356142T (en) 2007-03-15
NL300260I1 (en) 2007-05-01
EP1298211A3 (en) 2003-04-16
EP1207203A2 (en) 2002-05-22
NL300312I1 (en) 2008-02-01
EP1298211B1 (en) 2006-07-12
NL300266I1 (en) 2007-05-01
LU91385I2 (en) 2008-02-14
LU91321I2 (en) 2007-05-09
NL300262I1 (en) 2007-05-01
LU91385A9 (en)
DE122007000016I1 (en) 2007-05-24
NL300313I1 (en) 2008-02-01
DE69233639D1 (en) 2006-08-24
JP2004000269A (en) 2004-01-08
US7476389B1 (en) 2009-01-13
DE69233687T2 (en) 2007-10-18

Similar Documents

Publication Publication Date Title
DE69230637D1 (en) ventilator
DE69208991T2 (en) surgical Klammernähgerät
DE69218688D1 (en) tongs
DE69333814D1 (en) Genetic vaccine against the immunodeficiency virus
FI921493A0 (en) Science capsule formulationer with foerdroejd effekt.
NO20001227L (en) drugs
FI921168A0 (en) Inhalator.
NO923016L (en) inhalation devices
FI921089A0 (en) Termostatiskt an adjustable Blandningsventil.
NO921497D0 (en) adjustable armchair
DE69409182D1 (en) Adjustable, releasable catch connection
AT178199T (en) intubation
DE69215981T2 (en) cannula protection
NO933728L (en) Dosage Form
AT255906T (en) Antibodies to CD40
FI946064A (en) The vaccine composition containing the excipient
NO942027L (en) Kjönnssteroidaktivitetshemmere
NO934500D0 (en) Non-klorfluorcarbonaerosolformuleringer
NO931722D0 (en) Injeksjonsnaalanordning
NO922111D0 (en) Rapamycin-dimers
NO923128D0 (en) Farmasoeytisk sfaeroidformulering
NO940635D0 (en) Steroidsulfataseinhibitorer
DE69101753D1 (en) Decoy virus vaccine.
FI990115A (en) The inhaler
DE69207450T2 (en) stand

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
V448 Application of spc

Free format text: PRODUCT NAME: HPV6 VIRUS-LIKE PARTICLE; REGISTRATION NO/DATE: EU/1/06/357/001-017, EU/1/06/358/001-017; 20060920

Spc suppl protection certif: 12 2007 000 019

Filing date: 20070221

Free format text: PRODUCT NAME: HPV11 VIRUS-LIKE PARTICLE; REGISTRATION NO/DATE: EU/1/06/357/001-017, EU/1/06/358/001-017; 20060920

Spc suppl protection certif: 12 2007 000 017

Filing date: 20070221

Free format text: PRODUCT NAME: KOMBINATION AUS HPV6, HPV11, HPV 16 UND HPV18 VIRUS-LIKE PARTICLES; REGISTRATION NO/DATE: EU/1/06/357/001-017, EU/1/06/358/001-017; 20060920

Spc suppl protection certif: 12 2007 000 016

Filing date: 20070221

R071 Expiry of right

Ref document number: 595935

Country of ref document: EP